🧐 You missed something...
Top Market, Investing, and Business Insights for November
Here’s a recap of last month’s top market, investing, and business insights—from insiders and experts outside the mainstream media:
$930M in cash, very little debt, and FDA fast-tracked—who am I?
Radical new study shows other body parts can “remember.”
THIS tiny company riffed over 42 applications to the FDA—WTF?
THIS unheard-of beauty product mopped the floor with Estée Lauder.
And more. Let’s get to it!
Follow us on Instagram | YouTube | Advertise
Top Insights for November
1. 💸 $930M Cash. Little Debt. FDA Fast-Tracked—Who Am I?
FDA is laser-focused on ending obesity and they’re all in on this one drug that top investors are calling a “goldmine”. And, The Wall Street Journal called it a “gold rush”. The drug sucking up all the attention…GLP-1.
GLP-1 mimics a gut hormone, telling your brain you’re full, so you eat less.
There's a small biotech who sees this as their opportunity to explode in growth. In fact, FDA "nudged" them to pick up the pace, fast-tracking their GLP-1 drug to Phase 3. Investors heard—and their stock shot up 30%…Viking Therapeutics.
Here’s why we’re paying close attention…
Helping patients lose AND keep the weight off, unlike Ozempic.
Swimming in $930M cash and very little debt.
Good relations with FDA, entering Phase 3 trials.
Offers both an injectable and pill, broader patient appeal.
Share are up 531% in the last 12 months, with no approved drugs—plenty of room for more growth.
Fascinating research…
Patients taking Viking’s drug saw 14.7% weight loss in 13 weeks. Ozempic took 68 weeks for similar results.
All the benefits of GLP-1s for weight loss with very little side effects.
Improved blood sugar levels could help those at risk of diabetes or with metabolic issues.
Weight-loss market: ~$274B in 2024, projected ~$405B by 2034.
2. 😳 Your Kidney Has a Memory Too!—Radical New Study
Ever notice how your gut seems to know things before your brain catches on? Turns out, it’s not just “gut-instinct.” New research shows that cells—yes, even those in your gut—might have their own kind of memory. It’s not just your brain that remembers. This could shift how we tackle diseases from diabetes to cancer.
Non-brain cells, like kidney and nerve cells, can activate memory genes.
Scientists ran tests on kidney and nerve cells…
They exposed one group to a single, 12-minute dose of chemicals and another group to four shorter, 3-minute doses. The result? The cells with short breaks showed 400% more activity, while the one-time dose only boosted activity by 30%.
This shows that cells respond better with pauses, suggesting they "remember" the breaks. Turns out, recognizing patterns isn’t just for brain cells—all cells do it.
The university behind this has a knack for breakthroughs, turning research into significant revenue for drug companies… NYU… their greatest hits…
Developed the antibody used in Remicade, a popular drug for treating chronic inflammation.
Developed the first vaccines for polio, measles, rubella, and hepatitis B.
3 big players paying close attention…
Pfizer, could use it to tap into cell memory and rethink treatments for cancer and chronic diseases.
Roche, could use this to boost its efforts in making cancer treatments smarter, aiming to beat cells that remember how to resist drugs.
Eli Lilly, could use it to evolve their work in neuroscience and Alzheimer's research.
3. 💸 Ready to get serious about investing?
Then join our growing list of premium subscribers who have already placed themselves on the path to greater wealth by mirroring our stock ideas.
Subscribe today for just $9/month.
🚨 What you get when you become a premium subscriber ($13,890.80 value) 🚨
TOP 5 MARKET BEATING STOCK IDEAS ($5,000 value) picked with sniper precision, delivered to your inbox every Monday morning, before the market opens.
HIGH CONVICTION TRADE ALERTS ($1,690.80 value) throughout the week as we spot them.
Access to OUR COMMUNITY ($1,200 value) of fellow traders, where you can ask questions & post comments.
END OF THE MONTH SUMMARY ($600 value) of which ideas performed best.
NO GUESSWORK ($2,400 value). You'll get to see our entry point, stop loss, and profit target.
INSTANT ACCESS, no strings attached. No commitment. Cancel anytime.
UNCONVENTIONAL MARKET & MACRO INSIGHTS ($3,000 value), discover opportunities and risks not highlighted elsewhere.
MAKE MONEY or GET YOUR MONEY BACK GUARANTEE. If you subscribe today, use it actively for a year, and don't make money, we'll refund your payment and give you an extra year for free.
Get $13,890.80 worth of value for just $9/month to our premium newsletter. Hands down, Money Machine Newsletter is the most valuable investing service out there.
4. 🤨 THIS Tiny Company Riffed 42 Apps to the FDA – WTF?
A tiny unheard of company riffed over 42! applications to the FDA—they’re not messing around. Their competitor launched a similar product and the stock ballooned—pushing it to a 16-year high. Who’s the competitor? Philip Morris. And their darling product? Zyn…So, who wants to wet their beak and take some market share? Lucy.
Lucy submits 42 Premarket Tobacco applications to the FDA.
Here’s why we’re keeping a close eye on this one…
$10M raised in Series A from Y Combinator and RRE Ventures.
Uses lab-made nicotine, skipping the need for tobacco farming.
Innovation and FDA compliance make it a prime acquisition target.
Multiple products for adults craving a tobacco-free nicotine.
Lucy’s following Zyn’s playbook, which made Philip Morris’ stock boom. Their innovation and FDA compliance put them in the crosshairs for a potential MAJOR acquisition or IPO.
Tobacco-free nicotine market: ~$3B in 2023, projected ~$23B by 2030.
Community Spotlight
Newsletters from other independent thinkers you might find interesting.
👉 ChartScope, explore macroeconomics, crypto, global markets visually. Engage with data-driven insights.
👉 Weekly’s Commodity Insight, get expert insights and weekly market updates on commodities delivered in a clear, friendly format. Covering top commodity market movers, key trends, and helping you stay informed about your earth precious materials.
👉 Crypto Highlights, all the latest Crypto Market news in less than 2 minutes!! You will know everything you need to know saving hours of researching on your own.
👉 CryptoTalk Newsletter, crypto, finance, and investments. Everything you need to know in a daily and free newsletter to make better financial decisions in the future!
👉 Shebatrades, a concise daily market update covering Sheba's thoughts on the major market news and drivers of the day, followed by a discussion of portfolio action and new stock setups.
Top 3 Charts of the Week
1. 📈 Insane Revenue Growth by e.l.f
e.l.f. Beauty’s sales jumped 40%, smashing expectations, while big names like Estée Lauder saw drops.
Their low-cost "dupes" are winning over Gen Z and beyond.
e.l.f. is crushing it by selling great beauty products that don’t break the bank.
2. 🇨🇳 China Hits All-Time High Trade Surplus
China made way more money selling goods than it spent buying them, $785B record surplus.
China’s economy relies on selling products overseas because people aren’t spending much at home.
New U.S. tariffs could make things tense—cause price spikes and market instability.
3. 🤔 The New Bargain Giants (Temu & Shein)
Amazon’s new "Haul" offers cheap items to compete with bargain sites Temu and Shein.
Going after shoppers looking for the best deals, even if it means slower delivery.
Amazon wants to keep you from switching to cheaper shopping sites.
What did you think of today’s newsletter?
Enjoy this content? Follow us on Instagram, YoutTube, Linkedin
We take the responsibility of emailing you seriously. If you don't want to receive stock market updates and trading education anymore, you can unsubscribe at any time.
Nothing in this email is intended to serve as financial advice. Do your own research. See important disclaimer & terms of service.